He4: Human Epididymis Protein 4

All genderNo preparation required
MRP₹466725% off
circle logo
₹245 cashback

Effective price: ₹3255

testsTotal tests included (0)


    blood sample




    Age group

    Above 10 years

    The majority of epithelial ovarian cancer cells generate a protein called Human Epididymis Protein 4 (HE4). The HE4 level in the blood is determined using the HE4 test. In particular situations, this renders the HE4 test useful as a tumour marker.

    A woman with epithelial ovarian cancer has a significantly high concentration of HE4 in her blood. When HE4 levels rise, the HE4 test can be performed to check for cancer development or recurrence and gauge how well the treatment is working.

    Ovarian cancer is the fifth most common cause of cancer-related death among women. The most prevalent kind of ovarian cancer is epithelial. It contributes to 80% to 90% of ovarian cancer cases and develops in cells lining the ovaries' exterior.

    Endometrioid, Clear Cell, Serous, and Mucinous, are a few of the subcategories of epithelial ovarian cancer, with Serous being the most prevalent. According to several research studies, HE4 is typically elevated in Mucinous malignancies but not in the majority of Endometrioid and Serous epithelial ovarian cancers and around half of Clear Cell tumours. So, individuals with other forms of ovarian cancer, such as Germ Cell or Mucinous tumours, are not monitored with HE4.

    Women receiving treatment for epithelial ovarian cancer are followed up with Cancer Antigen 125 (CA-125) and Human Epididymis Protein 4. Before therapy, HE4 must be elevated to be effective as a tumour marker. The primary technique employed to monitor ovarian malignancies is CA-125; however, not all tumours have elevated levels. Hence, scientists are still looking for tumour indicators that are more accurate and precise.

    The HE4 test at Apollo 24|7 provides valuable insights into epithelial ovarian cancer. The test's findings could indicate any of the following:

    Epithelial ovarian cancer typically responds to treatment if HE4 and CA-125 levels were originally elevated and subsequently decreased after the treatment.

    If levels increase or remain unchanged, the malignancy has probably not responded. Following cancer treatment or surgery, rising levels of HE4 and CA-125 may be discovered during routine monitoring. This can mean that cancer has resurfaced. 

    An elevated ROMA score can indicate that the pelvic mass is more probable to be cancerous in a woman who suffers from a lump in her pelvis and will be having surgery.

    The test is ineffective in tracking a woman's ovarian cancer if her baseline HE4 is normal after a diagnosis of epithelial ovarian cancer.

    If you have non-epithelial ovarian cancer, this test would not be recommended. If your malignancy does not result in increased HE4 production, the HE4 test would not be practical as a monitoring tool. 

    Medically reviewed by Dr. Sanjaya Mishra, Radiation Oncology, Apollo Hospitals Old Sainik School Road, Bhubaneswar.

    packageTop Tests with He4: Human Epididymis Protein 4

    faqFrequently Asked Questions (FAQs)

    Frequently asked questions

    Most epithelial ovarian cancer cells, but not all, generate the protein known as Human Epididymis Protein 4 (HE4). The test is hence advantageous as a tumour marker in some situations. The Human Epididymis Protein 4 level in the blood is determined using the HE4 test.
    A woman with epithelial ovarian cancer typically has blood with noticeably higher levels of Human Epididymis Protein 4. When HE4 levels rise, the HE4 test may be used to check for cancer development or recurrence as well as to gauge how well the treatment is working.
    HE4 is more precise and effective in spotting early-stage ovarian cancer. In ovarian cancer, HE4 boosts the usefulness of Cancer Antigen 125 (CA125) as a tumour marker, and the sensitivity of the tumour marker is increased when both markers are used together.
    Renal dysfunction is the most frequent factor in false-positive values for HE4. Patients with innocuous gynaecological problems exhibit lower HE4 levels than individuals with renal impairment. Pseudo-positive HE4 readings are also observed in patients with liver or lung illness, effusions, or both.
    The HE4 reference threshold for healthy people is 85 pmol/l; for the pre and postmenopausal categories, it is 73 pmol/l and 94 pmol/l, respectively.
    Apollo 24

    Why should Apollo be your preferred healthcare partner?

    • 40 Years of legacy and credibility in the healthcare industry.
    • NABL certified multi-channel digital healthcare platform.
    • Affordable diagnostic solutions with timely and accurate test results.
    • Up to 60% discount on Doorstep Diagnostic Tests, Home Sample Collection.
    • An inventory of over 100+ laboratories, spread across the country, operating out of 120+ cities with 1200+ collection centers, serving over 1800+ pin codes.

    The information mentioned above is meant for educational purposes only and should not be taken as a substitute to your Physician’s advice. It is highly recommended that the customer consults with a qualified healthcare professional to interpret test results